Aitaj Badalova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aitaj Badalova has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Elnur Gasimov
Azerbaijan Medical University
2 shared publications - Emilya Balayeva
Azerbaijan Medical University, Baku, Azerbaijan, Azerbaijan
2 shared publications - Kubra Aliyeva
Azerbaijan Medical University, Baku, Azerbaijan, Azerbaijan
2 shared publications - Tahir Suleymanov
Department of Pharmaceutical Chemistry, Azerbaijan Medical University, Baku AZ1022, Azerbaijan
2 shared publications - Abolghasem Jouyban
Pharmaceutical Analysis Research Center, Pharmaceutical Sciences Institute, Tabriz University of Medical Sciences, Tabriz, Iran
1 shared publication - Behrouz Seyfinejad
Cellular and Molecular Research Center, Cellular and Molecular Medicine Research Institute, Urmia University of Medical Sciences, Urmia, Iran, Iran
1 shared publication
Latest Publications
- Open Access
- 2 July 2026
- Published by MDPI AG in Preprints.org
Development and Validation of an HPLC-UV Method for the Determination of Levofloxacin from a Prolonged–Release Mesh Implant in Rat Blood
Levofloxacin (LVX) is a broad-spectrum antibiotic whose systemic administration can be limited by adverse effects and suboptimal drug levels at infection sites. Implantable drug-loaded meshes offer a promising strategy for localized, prolonged delivery. This study developed and validated a simple, rapid, and reliable high-performance liquid chromatography with ultraviolet detection (HPLC-UV) method for quantifying LVX in rat blood to support the preclinical evaluation of a prolonged-release LVX-loaded polypropylene mesh. The method utilized a Zorbax SB-C18 column with an isocratic mobile phase of acetonitrile:0.1% orthophosphoric acid (80:20, v/v) at a flow rate of 1.4 mL/min, with detection at 296 nm. Validation according to ICH Q2(R2) guidelines demonstrated excellent linearity (R² = 0.999) over 1–8 µg/mL, accuracy (mean recovery 99.68%), and precision (intra- and inter-day CV < 0.3%). The limits of detection and quantification were 0.3 µg/mL and 1.0 µg/mL, respectively. The validated method was successfully applied to quantify LVX in rat plasma samples collected over 10 days post-implantation, confirming its suitability for pharmacokinetic studies of implant-based antibiotic delivery systems. This method provides a practical and robust analytical tool for routine preclinical assessment of LVX release and systemic exposure from localized delivery devices.
- 2 July 2026
- Published by MDPI AG in Preprints.org
Open AccessDevelopment and Validation of an HPLC-UV Method for the Determination of Levofloxacin from a Prolonged–Release Mesh Implant in Rat Blood
Levofloxacin (LVX) is a broad-spectrum antibiotic whose systemic administration can be limited by adverse effects and suboptimal drug levels at infection sites. Implantable drug-loaded meshes offer a promising strategy for localized, prolonged delivery. This study developed and validated a simple, rapid, and reliable high-performance liquid chromatography with ultraviolet detection (HPLC-UV) method for quantifying LVX in rat blood to support the preclinical evaluation of a prolonged-release LVX-loaded polypropylene mesh. The method utilized a Zorbax SB-C18 column with an isocratic mobile phase of acetonitrile:0.1% orthophosphoric acid (80:20, v/v) at a flow rate of 1.4 mL/min, with detection at 296 nm. Validation according to ICH Q2(R2) guidelines demonstrated excellent linearity (R² = 0.999) over 1–8 µg/mL, accuracy (mean recovery 99.68%), and precision (intra- and inter-day CV < 0.3%). The limits of detection and quantification were 0.3 µg/mL and 1.0 µg/mL, respectively. The validated method was successfully applied to quantify LVX in rat plasma samples collected over 10 days post-implantation, confirming its suitability for pharmacokinetic studies of implant-based antibiotic delivery systems. This method provides a practical and robust analytical tool for routine preclinical assessment of LVX release and systemic exposure from localized delivery devices.
- Open Access
Development and Validation of Spectrophotometric Method for Determination of Levofloxacin in Rat Plasma
A simple, rapid, and cost-effective UV–Vis spectrophotometric method was developed and validated for the determination of levofloxacin in rat plasma to support the evaluation of a novel antimicrobial mesh implant containing levofloxacin, chitosan, gelatin, tinctura propolis, citric, acid and glycerin. Plasma samples were treated with 0.1 M HCl, and absorbance was measured at 290 nm. The method was validated according to FDA and ICH guidelines, including assessments of linearity, sensitivity, accuracy, precision, and specificity. The calibration curve was linear over the concentration range of 2.5–12.5 μg/mL (R2 = 0.999, p < 0.001). The limit of detection and limit of quantification were 0.21 μg/mL and 0.62 μg/mL, respectively. Intra- and inter-day precision showed low relative standard deviation values (0.2% and 0.25%), while recovery ranged from 94.8% to 96.4%, confirming acceptable accuracy. No significant interference from plasma matrix components was observed. Compared with chromatographic techniques, the proposed method provides an accessible alternative for routine bioanalysis and therapeutic monitoring. The validated assay is suitable for assessing prolonged levofloxacin release from implantable drug delivery systems in preclinical studies.
Open AccessDevelopment and Validation of Spectrophotometric Method for Determination of Levofloxacin in Rat Plasma
A simple, rapid, and cost-effective UV–Vis spectrophotometric method was developed and validated for the determination of levofloxacin in rat plasma to support the evaluation of a novel antimicrobial mesh implant containing levofloxacin, chitosan, gelatin, tinctura propolis, citric, acid and glycerin. Plasma samples were treated with 0.1 M HCl, and absorbance was measured at 290 nm. The method was validated according to FDA and ICH guidelines, including assessments of linearity, sensitivity, accuracy, precision, and specificity. The calibration curve was linear over the concentration range of 2.5–12.5 μg/mL (R2 = 0.999, p < 0.001). The limit of detection and limit of quantification were 0.21 μg/mL and 0.62 μg/mL, respectively. Intra- and inter-day precision showed low relative standard deviation values (0.2% and 0.25%), while recovery ranged from 94.8% to 96.4%, confirming acceptable accuracy. No significant interference from plasma matrix components was observed. Compared with chromatographic techniques, the proposed method provides an accessible alternative for routine bioanalysis and therapeutic monitoring. The validated assay is suitable for assessing prolonged levofloxacin release from implantable drug delivery systems in preclinical studies.